Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03817749
Other study ID # H18-02930
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 6, 2019
Est. completion date December 31, 2020

Study information

Verified date April 2021
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-prandial hyperglycemic excursions induce a cascade of deleterious effects on the body, including increased inflammation, production of reactive oxygen species, and impaired cardiovascular function. Ingestion of an exogenous oral ketone supplement blunts hyperglycemia in response to an oral glucose tolerance test. Accordingly, it is hypothesized that exogenous ketone supplement ingestion prior to a meal could be an effective strategy for blunting postprandial hyperglycemia. Therefore, the purpose of this study is to investigate the effect of short-term (14-days) pre-meal exogenous ketone supplementation on glucose control, cardiovascular function, inflammation, and oxidative stress in individuals at an elevated risk of type 2 diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date December 31, 2020
Est. primary completion date March 1, 2020
Accepts healthy volunteers No
Gender All
Age group 30 Years to 69 Years
Eligibility Inclusion Criteria: - Elevated waist circumference (>102 cm for males, >88 cm for females) and/or Obesity (BMI > 30 kg/m2) and/or Diagnoses of prediabetes based on A1C (5.7-6.4%) and/or fasting plasma glucose (5.6-6.9 mmol/l) using ADA criteria Exclusion Criteria: - Competitively trained endurance athlete - Actively attempting to lose weight - History of mental illness or existing neurological disease(s) - Previous cardiovascular events (i.e., heart attack, stroke) - Diagnoses of diabetes - Hypoglycemia - Irritable bowel syndrome or inflammatory bowel disease - Taking medication that may interfere with insulin sensitivity - Currently following a ketogenic diet or taking ketone supplements - Unable to commit for 2 separate 14-day trials and unable to follow a controlled diet

Study Design


Intervention

Dietary Supplement:
Exogenous ketone monoester
Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.

Locations

Country Name City State
Canada University of British Columbia, Okanagan. Kelowna British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose control Post-prandial glucose excursions will be measured by continuous glucose monitoring using the iPro2 CGM by Medtronic in both the active and placebo supplement conditions. Post-prandial glucose following breakfast, lunch, and dinner will be averaged together. 2 hours after a meal
Secondary Change from baseline flow mediated dilation at 14 days Vascular function will be assessed by flow mediated dilation of the brachial artery using vascular ultrasound. A cuff will affixed on the forearm, distal to the brachial artery and will be inflated for 5 minutes. Flow mediation dilation will be measured over a 3-minute period following cuff release. Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline histone acetylation at 14 days Histone H3 acetylation status will be quantified by flow cytometry using conjugated acetyl-histone H3 antibody specific for Lys9 (Pacific Blue 445) and the conjugated acetyl-histone H3 antibody specific for Lys14 (Alexa Fluor 488). Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline mitochondrial superoxide production at 14 days Oxidative Stress will be measured by mitochondrial superoxide production in blood lymphocytes, monocytes, and neutrophils by flow cytometry using the MitoSOX red assay (ThermoFisher #M36008) and total intracellular ROS via the DCFDA assay (Sigma #D6883) Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline cognition (executive functions) at 14 days Cognition will be assessed using a customized battery of psychometrically validated tests within the domain of executive functions using the iPad-based app BrainBaseline. The tests will be the Stroop test, task-switching test, digit-symbol substitution test, and the n-back test. Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline plasma glucose at 14 days Venous blood samples will be taken and plasma glucose will be measured using a hexokinase method. Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline plasma insulin at 14 days Venous blood samples will be taken and plasma insulin will be measured using a high-sensitivity human insulin ELISA. Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline plasma free fatty acids at 14 days Venous blood samples will be taken and free fatty acids will be measured by colorimetric assay. Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline interleukin-1(IL)-1beta at 14 days Mature IL-1beta secretion will be quantified by ELISA run in duplicate Day 0 (Pre-intervention) and Day 14 (post-intervention)
Secondary Change from baseline caspase-1 activation at 14 days Caspase-1 activation will be quantified by flow cytometry. The fluorescent inhibitor probe FAM-YVAD-FMK binds covalently to activated caspase-1 and emits at 530nm Day 0 (Pre-intervention) and Day 14 (post-intervention)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A